BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25809780)

  • 1. An estrogen-induced endometrial hyperplasia mouse model recapitulating human disease progression and genetic aberrations.
    Yang CH; Almomen A; Wee YS; Jarboe EA; Peterson CM; Janát-Amsbury MM
    Cancer Med; 2015 Jul; 4(7):1039-50. PubMed ID: 25809780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endometrial hyperplasia-related inflammation: its role in the development and progression of endometrial hyperplasia.
    Kubyshkin AV; Aliev LL; Fomochkina II; Kovalenko YP; Litvinova SV; Filonenko TG; Lomakin NV; Kubyshkin VA; Karapetian OV
    Inflamm Res; 2016 Oct; 65(10):785-94. PubMed ID: 27312112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of PTEN, estrogen receptor α and progesterone receptor expression in endometrial hyperplasia using tissue microarray.
    Pieczyńska B; Wojtylak S; Zawrocki A; Biernat W
    Pol J Pathol; 2011 Sep; 62(3):133-8. PubMed ID: 22102068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
    Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
    Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA.
    Socolov D; Socolov R; Lupascu IA; Rugina V; Gabia O; Garauleanu DM; Carauleanu A
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):355-62. PubMed ID: 27483717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of Wdr13 knockout female mice uteri: a model for human endometrial hyperplasia.
    Singh S; Pavuluri S; Jyothi Lakshmi B; Biswa BB; Venkatachalam B; Tripura C; Kumar S
    Sci Rep; 2020 Sep; 10(1):14621. PubMed ID: 32883989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of drug-paste separated moxibustion on expression of estrogen, progestogen and their endometrial receptor mRNA in rats with primary dysmenorrhea].
    Fan YS; Miao FR; Liao AN; Xu F
    Zhen Ci Yan Jiu; 2013 Oct; 38(5):352-7. PubMed ID: 24308180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic options for management of endometrial hyperplasia.
    Chandra V; Kim JJ; Benbrook DM; Dwivedi A; Rai R
    J Gynecol Oncol; 2016 Jan; 27(1):e8. PubMed ID: 26463434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history.
    Epplein M; Reed SD; Voigt LF; Newton KM; Holt VL; Weiss NS
    Am J Epidemiol; 2008 Sep; 168(6):563-70; discussion 571-6. PubMed ID: 18682485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endometrial tumorigenesis in Pten(+/-) mice is independent of coexistence of estrogen and estrogen receptor α.
    Joshi A; Wang H; Jiang G; Douglas W; Chan JS; Korach KS; Ellenson LH
    Am J Pathol; 2012 Jun; 180(6):2536-47. PubMed ID: 22503752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of levonorgestrel-releasing intrauterine system on endometrial estrogen and progesterone receptors in patients with endometrial hyperplasia].
    Weng M; Li L; Feng S; Xie M; Hong S
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Sep; 32(9):1350-4. PubMed ID: 22985581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical reaction of the glandular epithelium in endometrial hyperplasia compared to endometrial carcinoma.
    Stoenescu VE; Niculescu M; Novac L; Manolea MM; Tomescu PI; Dijmărescu AL; Novac MB; Tudorache Ş; Iliescu DG
    Rom J Morphol Embryol; 2017; 58(3):791-800. PubMed ID: 29250656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
    Jiang XF; Tang QL; Li HG; Shen XM; Luo X; Wang XY; Lin ZQ
    J Obstet Gynaecol Res; 2013 Apr; 39(4):855-63. PubMed ID: 23106983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart and Neural Crest Derivatives Expressed Transcript 2 (HAND2): a novel biomarker for the identification of atypical hyperplasia and Type I endometrial carcinoma.
    Buell-Gutbrod R; Cavallo A; Lee N; Montag A; Gwin K
    Int J Gynecol Pathol; 2015 Jan; 34(1):65-73. PubMed ID: 25473755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis.
    Raffone A; Travaglino A; Saccone G; Viggiani M; Giampaolino P; Insabato L; Mollo A; De Placido G; Zullo F
    Arch Gynecol Obstet; 2019 Jun; 299(6):1511-1524. PubMed ID: 30915635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the estradiol-mediated endometrial gland formation by the antigestagen onapristone in rabbits: relationship to uterine estrogen receptors.
    Chwalisz K; Hegele-Hartung C; Fritzemeier KH; Beier HM; Elger W
    Endocrinology; 1991 Jul; 129(1):312-22. PubMed ID: 2055191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expressions of aromatase protein and sex hormone receptor in endometrial lesions].
    Ma XX; Zhang SL; Gao S; Lu JM; Dong F
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):395-8. PubMed ID: 16831363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of progesterone receptors (PR-A and PR-B) expression as predictors for relapse after successful therapy of endometrial hyperplasia: a retrospective cohort study.
    Sletten ET; Arnes M; Lyså LM; Larsen M; Ørbo A
    BJOG; 2019 Jun; 126(7):936-943. PubMed ID: 30548528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supervised clustering of immunohistochemical markers to distinguish atypical and non-atypical endometrial hyperplasia.
    Laas E; Ballester M; Cortez A; Gonin J; Canlorbe G; Daraï E; Graesslin O
    Gynecol Endocrinol; 2015 Apr; 31(4):282-5. PubMed ID: 25495249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chloroform Fraction of
    Olowofolahan AO; Akinjiola O; Olanlokun JO; Oyebode OT; Aina OO; Olorunsogo OO
    Anticancer Agents Med Chem; 2023; 23(11):1298-1308. PubMed ID: 36757042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.